Logo image of DMTK

DERMTECH INC (DMTK) Stock Fundamental Analysis

NASDAQ:DMTK - Nasdaq - US24984K1051 - Common Stock - Currency: USD

0.094  -0.01 (-11.32%)

After market: 0.095 +0 (+1.06%)

Fundamental Rating

2

Overall DMTK gets a fundamental rating of 2 out of 10. We evaluated DMTK against 572 industry peers in the Biotechnology industry. DMTK may be in some trouble as it scores bad on both profitability and health. DMTK is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year DMTK has reported negative net income.
DMTK had a negative operating cash flow in the past year.
In the past 5 years DMTK reported 4 times negative net income.
DMTK had a negative operating cash flow in each of the past 5 years.
DMTK Yearly Net Income VS EBIT VS OCF VS FCFDMTK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of DMTK (-87.04%) is worse than 73.69% of its industry peers.
DMTK's Return On Equity of -224.09% is on the low side compared to the rest of the industry. DMTK is outperformed by 71.95% of its industry peers.
Industry RankSector Rank
ROA -87.04%
ROE -224.09%
ROIC N/A
ROA(3y)-57.34%
ROA(5y)-43.66%
ROE(3y)-99.56%
ROE(5y)-68.72%
ROIC(3y)N/A
ROIC(5y)N/A
DMTK Yearly ROA, ROE, ROICDMTK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100 -150

1.3 Margins

DMTK has a better Gross Margin (8.51%) than 74.22% of its industry peers.
DMTK does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 8.51%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DMTK Yearly Profit, Operating, Gross MarginsDMTK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800

More info and screens

3

2. Health

2.1 Basic Checks

DMTK does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, DMTK has more shares outstanding
DMTK has more shares outstanding than it did 5 years ago.
The debt/assets ratio for DMTK has been reduced compared to a year ago.
DMTK Yearly Shares OutstandingDMTK Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
DMTK Yearly Total Debt VS Total AssetsDMTK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -8.44, we must say that DMTK is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of DMTK (-8.44) is worse than 73.69% of its industry peers.
DMTK has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
DMTK's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. DMTK outperforms 49.83% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.44
ROIC/WACCN/A
WACC10.37%
DMTK Yearly LT Debt VS Equity VS FCFDMTK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M

2.3 Liquidity

DMTK has a Current Ratio of 3.53. This indicates that DMTK is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.53, DMTK is doing worse than 61.85% of the companies in the same industry.
DMTK has a Quick Ratio of 3.46. This indicates that DMTK is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of DMTK (3.46) is worse than 61.15% of its industry peers.
Industry RankSector Rank
Current Ratio 3.53
Quick Ratio 3.46
DMTK Yearly Current Assets VS Current LiabilitesDMTK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

5

3. Growth

3.1 Past

DMTK shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 30.77%, which is quite impressive.
DMTK shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.80%.
Measured over the past years, DMTK shows a very strong growth in Revenue. The Revenue has been growing by 37.45% on average per year.
EPS 1Y (TTM)30.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.14%
Revenue 1Y (TTM)9.8%
Revenue growth 3Y37.45%
Revenue growth 5YN/A
Sales Q2Q%10.58%

3.2 Future

DMTK is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.08% yearly.
Based on estimates for the next years, DMTK will show a small growth in Revenue. The Revenue will grow by 6.40% on average per year.
EPS Next Y35.19%
EPS Next 2Y15.08%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year16.8%
Revenue Next 2Y6.4%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
DMTK Yearly Revenue VS EstimatesDMTK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M
DMTK Yearly EPS VS EstimatesDMTK Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

DMTK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DMTK. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DMTK Price Earnings VS Forward Price EarningsDMTK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DMTK Per share dataDMTK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as DMTK's earnings are expected to grow with 15.08% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.08%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DMTK!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DERMTECH INC

NASDAQ:DMTK (6/26/2024, 8:00:02 PM)

After market: 0.095 +0 (+1.06%)

0.094

-0.01 (-11.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2024-05-14/amc
Earnings (Next)08-01 2024-08-01/amc
Inst Owners1.25%
Inst Owner Change-0.11%
Ins Owners14.8%
Ins Owner Change0%
Market Cap3.29M
Analysts43.33
Price Target1.53 (1527.66%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.37%
Min EPS beat(2)2.83%
Max EPS beat(2)7.91%
EPS beat(4)4
Avg EPS beat(4)9.33%
Min EPS beat(4)0.28%
Max EPS beat(4)26.31%
EPS beat(8)7
Avg EPS beat(8)4.76%
EPS beat(12)7
Avg EPS beat(12)-0.55%
EPS beat(16)9
Avg EPS beat(16)-3.77%
Revenue beat(2)0
Avg Revenue beat(2)-5.25%
Min Revenue beat(2)-5.62%
Max Revenue beat(2)-4.87%
Revenue beat(4)1
Avg Revenue beat(4)-1.59%
Min Revenue beat(4)-5.62%
Max Revenue beat(4)5.68%
Revenue beat(8)2
Avg Revenue beat(8)-4.65%
Revenue beat(12)3
Avg Revenue beat(12)-4.35%
Revenue beat(16)7
Avg Revenue beat(16)3.66%
PT rev (1m)-26.59%
PT rev (3m)-46.43%
EPS NQ rev (1m)-10.64%
EPS NQ rev (3m)-0.78%
EPS NY rev (1m)0%
EPS NY rev (3m)0.25%
Revenue NQ rev (1m)-7.64%
Revenue NQ rev (3m)-8.9%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.19%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.21
P/FCF N/A
P/OCF N/A
P/B 0.08
P/tB 0.08
EV/EBITDA N/A
EPS(TTM)-2.7
EYN/A
EPS(NY)-2.12
Fwd EYN/A
FCF(TTM)-2.07
FCFYN/A
OCF(TTM)-2.06
OCFYN/A
SpS0.45
BVpS1.14
TBVpS1.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -87.04%
ROE -224.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 8.51%
FCFM N/A
ROA(3y)-57.34%
ROA(5y)-43.66%
ROE(3y)-99.56%
ROE(5y)-68.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.7%
Cap/Sales 0.91%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.53
Quick Ratio 3.46
Altman-Z -8.44
F-Score3
WACC10.37%
ROIC/WACCN/A
Cap/Depr(3y)174.84%
Cap/Depr(5y)226.26%
Cap/Sales(3y)17.22%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.14%
EPS Next Y35.19%
EPS Next 2Y15.08%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)9.8%
Revenue growth 3Y37.45%
Revenue growth 5YN/A
Sales Q2Q%10.58%
Revenue Next Year16.8%
Revenue Next 2Y6.4%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y23.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.62%
EBIT Next 3Y9.65%
EBIT Next 5YN/A
FCF growth 1Y9.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y5.43%
OCF growth 3YN/A
OCF growth 5YN/A